• 1
    Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thoracic Surg 1999; 67: 7907
  • 2
    Mikhaeel NG, Timothy AR, Hain S, O'Doherty MJ, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma. Leukaemia Lymphoma 2000; 39: 54353
  • 3
    Hain SF, O'Doherty MJ, Timothy AR et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83: 8639
  • 4
    Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine–labelled deoxyglucose. J Urol 1996; 155: 9948
  • 5
    Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 10811
  • 6
    Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86: 5126
  • 7
    Oyama N, Akino H, Suzuki Y et al. The increased accumulation of [18F]Fluorodeoxyglucose in untreated prostate cancer. Jap J Clin Oncol 1999; 29: 6239
  • 8
    Heicappell R, Muller-Mattheis V, Reinhardt M et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)]-2-deoxy-d-glucose. Eur Urol 1999; 36: 5827
  • 9
    Sanz G, Robles JE, Gimenez M, Arcena J, Sanchez D, Rodriguez-Rubio F. Positron emission tomography with 18 fluorine-labelled deoxyglucose: utility in localized and advance prostate cancer. BJU Int 1999; 84: 102831
  • 10
    Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer. initial findings of PET with 2-deoxy-[F-18] fluoro-d-glucose. Radiology 1996; 199: 7516
  • 11
    Yeh SD, Imbriaco M, Larson SM et al. Detection of bony metastases of androgen-independent prostate cancer by FDG-PET. Nucl Med Biol 1996; 23: 6937
  • 12
    Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 33759
  • 13
    Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18F FDG-PET for the assessment of residual masses on CT after treatment of lymphomas. Ann Oncol 2000; 11: S147S150
  • 14
    Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 315
  • 15
    Schelling M, Avril N, Nahrig J et al. Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 168995
  • 16
    Oyama N, Akino H, Suzuki Y et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Comm 2001; 22: 9639
  • 17
    Nunez R, Macapinlac HA, Yeung HW et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nuclear Med 2002; 43: 4655
  • 18
    Kotzerke J, Prang J, Neumaier B et al. Experience with carbon-11 choline positron emission tomography in prostate cancer. EJNM 2000; 27: 14159
  • 19
    Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using choline-11-choline. J Nucl Med 1998; 39: 9905
  • 20
    DeGrado TR, Coleman RE, Wang S et al. Synthesis and evaluation of 18F-labelled choline as an oncological tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61: 1107
  • 21
    Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43: 1816
  • 22
    Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in the diagnosis of renal cell carcinoma. Urologe 1996; 35: 14650
  • 23
    Ramdave S, Thomas GW, Berlangiere SU et al. Clinical role of F-18 Fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 82530
  • 24
    Miyakita H, Tokunaga M, Onda H et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9: 158
  • 25
    Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischmann AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52: 5105
  • 26
    Hain SF, Gleadle J, Maisey MN. FDG-PET in the differentiation of thrombus and tumour in renal cell carcinoma. Clin Nucl Med 1999; 24: 81920
  • 27
    Safaei A, Figlin R, Hoh CK et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002; 57: 5662
  • 28
    Seto E, Segall GM, Terris MK. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology 2000; 55: 286
  • 29
    Poggi MM, Patronas N, Buttman JA, Hewitt SM, Fuller B. Intramedullary spinal cord metastases from renal cell carcinoma: detection by positron emission tomography. Clin Nucl Med 2001; 26: 8379
  • 30
    Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe 1999; 38: 4650
  • 31
    Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 Fluorodeoxyglucose positron emission tomography in patients with bladder cancer. EJNM 1997; 24: 61520
  • 32
    Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996; 37: 1805
  • 33
    Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography of residual radiological abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996; 14: 163741
  • 34
    Cremerius U, Effert PJ, Adam G et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998; 39: 81522
  • 35
    Sugawara Y, Zasadny KR, Grossman HB et al. Germ cell tumour. differentiation of viable tumour, mature teratoma and necrotic tissue with FDG PET and kinetic modelling. Radiology 1999; 211: 24956
  • 36
    De Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2–18fluoro-2-deoxy-d-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 37404
  • 37
    Lodge MA, Lucas JD, Marsden PK et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 2230
  • 38
    Bokmeyer C, Kollmannsberger C, Oechsle K et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F] FDG PET. Br J Cancer 2002; 86: 50611
  • 39
    Hain SF, O'Doherty MJ, Timothy A et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27: 5904
  • 40
    Warde P, Jewett MA. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 1998; 25: 42533
  • 41
    Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumours. Urology 1994; 44: 54852
  • 42
    Cremerius U, Wildberger JE, Borchers H et al. Does positron emission tomography using 18-Fluoro-2-deoxyglucose improve clinical staging of testicular cancer? – results in 50 patients. Urology 1999; 54: 9004
  • 43
    Albers P, Bender H, Yilmaz H et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumours. Urology 1999; 53: 80811